MUDr. Tomáš Doležal, Ph.D.
Research specialist, Department of Pharmacology
Correspondence Address:
Kamenice 753/5, 625 00 Brno
E‑mail: |
---|
Total number of publications: 13
2022
-
Health and economic impact of subcutaneous allergen immunotherapy in patients with pollen-induced allergic rhinoconjunctivitis: real-word evidence from the Czech Republic
IMMUNOTHERAPY, year: 2022, volume: 14, edition: 14, DOI
-
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, year: 2022, volume: 22, edition: 8, DOI
-
Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study
Expert Review of Gastroenterology & Hepatology, year: 2022, DOI
-
Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide
Pharmaceuticals, year: 2022, volume: 15, edition: 10, DOI
2021
-
Accession Site Does Not Influence the Risk of Stroke after Diagnostic Coronary Angiography or Intervention: Results from a Large Prospective Registry
CEREBROVASCULAR DISEASES EXTRA, year: 2021, volume: 11, edition: 3, DOI
-
Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn's Disease
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, year: 2021, volume: 19, edition: 4, DOI
-
Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, year: 2021, volume: 21, edition: 6, DOI
-
Smoking in women with chronic vaginal discomfort is not associated with decreased abundance of Lactobacillus spp. but promotes Mobiluncus and Gardnerella spp. overgrowth - secondary analysis of trial data including microbiome analysis
ČESKÁ GYNEKOLOGIE, year: 2021, volume: 86, edition: 1, DOI
2020
-
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Cancers, year: 2020, volume: 12, edition: 4, DOI
-
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry
Expert Opinion on Biological Therapy, year: 2020, volume: 20, edition: 2, DOI